ARTICLE | Company News
Cantabio, University of Antioquia deal
June 27, 2016 7:00 AM UTC
Cantabio and the university’s Neuroscience Research Group will evaluate Cantabio’s small molecule chaperone therapeutic candidates targeting DJ-1 (PARK7) to treat Parkinson’s disease (PD). The partne...